Clinical Trial Update: Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating recombinant human C1 esterase inhibitor (Conestat alfa) for preventing acute ischemic stroke and acute kidney injury after transcathe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Stroke

Drugs mentioned

• Conestat Alfa (conestat alfa)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Acute Ischemic Stroke, Acute Renal Injury | Phase 2 | Status: COMPLETED